- Development of a Scalable and Practical Synthesis of AB928, a Dual A2a/A2bReceptor Antagonist
-
AB928 is a potent and selective dual antagonist of the A2a and A2b receptors, which is currently in clinical trials. Here, we report the development of two scalable and practical syntheses of AB928. The first-generation synthesis was used to successfully
- Debien, Laurent P. P.,Jeffrey, Jenna L.,Leleti, Manmohan R.,Miles, Dillon H.,Powers, Jay P.,Rosen, Brandon R.,Sharif, Ehesan U.
-
p. 1254 - 1261
(2020/08/14)
-
- PROCESSES FOR PREPARING AMINOPYRIMIDINE COMPOUNDS
-
Provided herein are improved processes for preparing aminopyrimidine compounds of Formula (I). The disclosed processes advantageously proceed through a β-diketoester intermediate of Formula (A) and avoid the direct linking of a pyrimidine and phenyl moiet
- -
-
Paragraph 0079
(2020/12/29)
-
- As opioid receptor antagonists or inverse agonists of the novel compounds
-
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
- -
-
Paragraph 0335-0337; 0338-0340
(2016/10/08)
-
- DIFLUOROMETHYLENE COMPOUND
-
The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound. More specifically, the present invention relates to a compound represented by the formula (I): wherein R1 is -Q1-A1 or the like; R2 is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W1, W2, W3 and W4 are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR3 or the like.
- -
-
Paragraph 0505-0507
(2015/06/16)
-
- NOVEL PKC INHIBITORS
-
The present invention relates to new kinase inhibitors, more specifically PKCθ inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular,
- -
-
Page/Page column 46
(2012/12/13)
-
- Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents
-
A series of boron-containing benzoxaborole compounds was designed and synthesized for a structure-activity relationship investigation surrounding 7-(HOOCCH2CH2)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (1) with the goal of discovering
- Zhang, Yong-Kang,Plattner, Jacob J.,Freund, Yvonne R.,Easom, Eric E.,Zhou, Yasheen,Gut, Jiri,Rosenthal, Philip J.,Waterson, David,Gamo, Francisco-Javier,Angulo-Barturen, Inigo,Ge, Min,Li, Zhiya,Li, Lingchao,Jian, Yong,Cui, Han,Wang, Hailong,Yang, Jian
-
experimental part
p. 644 - 651
(2011/03/18)
-
- DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS
-
The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
- -
-
-
- Dual Pharmacophores - PDE4-Muscarinic Antagonistics
-
The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.
- -
-
Page/Page column 50
(2009/08/18)
-
- Dual Pharmacophores - PDE4-Muscarinic Antagonistics
-
The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
- -
-
Page/Page column 52
(2009/08/16)
-
- Dual Pharmacophores - PDE4-Muscarinic Antagonistics
-
The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.
- -
-
Page/Page column 53
(2009/08/18)
-
- BIS-ARYL KINASE INHIBITORS AND METHOD
-
Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
- -
-
Page/Page column 39
(2010/11/25)
-
- PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA
-
Disclosed are novel compounds of formula (I) wherein R1, R2, R3 , R4 and A are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders
- -
-
Page/Page column 43-44
(2008/06/13)
-